Transforming growth factor-P (TGF3) is a pleiotropic growth factor, which plays a critical role in modulating cell growth, differentiation and plasticity. There is increasing evidence that after cells lose their sensitivity to TGF3-mediated growth inhibition, autocrine TGF3 signaling may potentially promote tumor progression. In order to further understand the role of TGF3 in mammary transformation, the MDA-MB-231 human metastatic breast cancer cell line was used to generate stable cell lines expressing a dominant negative TGFP type II receptor (dnTPRII). Expression of dnTPRII was confirmed by affinity labeling cell surface receptors with 12 1I-TGFPI and immunoprecipitating the affinitylabeled exogenous receptor via its HA tag. The dnTPRII was determined to be functional in that it could associate with the type I TGFP receptor and prevent it from initiating signal transduction. Results to date indicate that the basal migratory potential of dnTPRII expressing cells is impaired, and this impairment appears to be TGFP specific. Biochemical experiments are currently underway to identify the signal transducers perturbed by dnT3RII expression which impair motility, and which may, in turn, be relevant to TGFP-mediated invasion and metastases.
Introduction
The overall goal of this research was to elucidate the complex role of transforming growth factor P3s (TGFp3s) in sequential stages of mammary epithelial transformation, and to determine whether blocking autocrine TGFP signaling in MDA-231 human breast cancer cells would affect their metastatic phenotype in vitro and in vivo. This knowledge is of potential importance for the development of rational therapeutic approaches in human breast carcinoma.
Body Specific Aim 1
The purpose of this Aim was to generate MMTV/tTA + tet-op/TGFP3 1 s223/225 mice. As stated in our 1999 Annual report, although MMTV/tTA mRNA was expressed in the mammary glands of the F 1 bigenic animals we generated, expression levels were very low, and tet-op/TGFp 1 mRNA was not detectable. Since this may have been due to the low level of expression of the MMTV/tTA, we obtained other MMTV/rtTA founder lines (1 heterozygous male and 1 heterozygous female) with more robust MMTV expression in the mammary gland from Dr. Lewis Chodosh (University of Pennslvania, PA). Unfortunately, the male MMTV/rtTA mouse died while being quarantined in our animal facility and the female MMTV/rtTA mouse died shortly after being released from quarantine. Consequently, breedings between these mice and our tet-op/TGF 3 1 homozygous founder lines could not be set-up in order to generate the desired bigenic mice. We have since obtained two more male MMTV-rtTA mice from Dr. Chodosh. These mice are currently being quarantined in our mouse facilty. Once the two male MMTV-rtTA mice have been released from quarantine (scheduled for November 5, 2001) , breeding pairs will be established between the MMTV-rtTA males and the tet-op/TGFf 1l females in order to generate the bigenic mice required for our studies.
Specific Aim 2
This Aim initially proposed to study the effect of mammary TGF 3 1 overexpression on different stages of breast transformation in MMTV/neu + TGFa bigenic mice. Due to the complexity of generating a mouse between these two bigenics bearing four different transgenes, two alternative approaches were proposed in our 1999 Annual Report. However, until an appropriate MMTV/tTA + tet-op/TGFP 1 bigenic mouse is generated, these studies cannot be pursued. GAEdnT •RII This Aim initially proposed to test the pGABE effect of antisense TGFf31 and antisense TGFP32 on pg S FA MDA-231 human breast cancer cells. However, as stated in our 2000 Annual Report, since we were Stably Transfect MDA-MB-231 Breast Cancer Cells unable to generate stable transfectants with sustained expression of antisense, we chose to disrupt autocrine Sort Green Fluorescent Cells by Flow Cytometry TGFP signaling in these cells by stably expressing a dominant negative type II TGFP3 receptor. to an invariant lysine found in the ATP-binding site of subdomain II in all protein kinases, and even its substitution with arginine results in loss of kinase activity (Wrana et al., 1992) . The control pGABE and dnTP3RII encoding vectors are modified versions of the commonly used retroviral vector pBABE in which the puromycin cassette has been replaced by enhanced green fluorescent protein (GFP). In this construct, dnTP3RII-K277R is HA tagged, and its expression is driven by the viral long terminal repeat (LTR), while expression of GFP is driven by the SV40 promoter ( Fig. 1) . Following transfection, cells expressing GFP were sorted by flow cytometry. After multiple sortings, a pool of transfectants, the majority of which expressed GFP, was obtained ( Fig. 1) . Clones were then isolated by sorting individual cells from the positive pool.
Specific Aim 3

Verification of dnT/3R1I-K277R Expression in MDA-MB-231 Cells
To verify that the dnTP3RII-K277R mutant was indeed expressed in the pool and clones of MDA-MB-231 cells expressing EGFP, cell surface receptors were affinity labeled with 1 2 SI-TGF 31 (Fig. 2) . As expected, cell surface labeling of parental cells resulted in the labeling of three proteins corresponding to the endogenous type 1, 11, and III TGFP3 receptors expressed in these cells. There was little or no change in the amount of labeling observed in the control GABE clones. However, clones expressing dnTP3RII-K277R, displayed a significant increase in the amount of labeled type II receptor, suggesting that the exogenous receptor was indeed expressed. A similar pattern of labeling was observed in the GABE pool from which the GABE clones were sorted, and the dnTP3RII-K277R pool from which the dnTP3RII-K277R clones were sorted.
In order to confirm that this increase in the labeling of the type II receptor was indeed due to expression of dnT13RII-K277R, extracts from affinity labeled cells were immunoprecipitated with an anti-HA antibody to pull down the HA-tagged dnTP3RII-K277R. As shown in Fig. 3 , the anti-HA antibody immunoprecipitated a labeled type II receptor in the pool and clones expressing dnTP3RII-K277R, but not S•, Receptor Labeling. MDA-MB-231 parental cells as well Tagged dnTPRII. Cells were affinity labeled with 2.5 as clones and pools stably expressing dnTPRII or the ng/ml 12 5 1-TGFP1, lysed and incubated with a mouse control GABE vector were affinity labeled with 2.5 ng/ml monoclonal anti-HA antibody for immunoprecipitation of 125 I-TGF[I and cross-linked with BS 3 . Labeled ligand-HA-tagged dnTflRII. Immunoprecipitates were resolved receptor complexes were resolved by SDS-PAGE using a by SDS-PAGE using a 7.5% polyacrylamide gel and 3-12% gradient gel and visualized by autoradiography.
visualized by autoradiography. Affinity labeled, but non-Molecular weight markers are indicated on the left, and immunoprecipitated G15-5 cells were loaded as a TGFP3 receptors are indicated on the right, reference (NIP).
in the control GABE pool or clones, confirming transgene expression. The type I and type III TGFI3 receptors appeared to co-immunoprecipitate with dnTO3RII-K277R in these experiments. This was confirmed in subsequent co-immunoprecipitation experiments (see Fig. 4 below).
Evaluation of dn T/RII-K2 77R Function in MDA-MB-231 Cells
Having ascertained that dnT[3RII-K277R was indeed expressed in the MDA-MB-231 pool and clones, we then wished to determine whether it was functional. If so, it should associate with the type I receptor, prevent the endogenous type II receptor from associating with, phosphorylating, and activating the type I receptor, and therefore prevent the type I receptor from initiating signal transduction. The ability of dnTP3RII-K277R to act as a dominant negative was evaluated utilizing four different assays. First, co-immunoprecipitation experiments were performed in order to determine whether dnTP3RI-K277R could in fact associate with the type I TGFP3 receptor (Tf3RI). Next, the effect of dnT[3RII-K277R expression on various steps of TGF[3-mediated signal transduction was examined by i) immunoblot analysis of phospho-Smad2, ii) immunofluorescence staining to monitor Smad2 translocation to the nucleus, and iii) transcriptional activation of TGF[3-responsive reporter constructs.
i) Co-immunoprecipitation of TI3RI with dnTP3RII-K277R
The co-immunoprecipitation experiments revealed that when affinity labeled cells expressing dnTP3RII-K277R were immunoprecipitated with an anti-HA antibody, a labeled protein the size of a type I receptor co-immunoprecipitated with the dnTP3RII-K277R ( Fig. 3 and Fig. 4 , right panellast lane). We confirmed that this was TP3RI by immunoprecipitating similarly labeled cells with various TGF[3 superfamily type I receptor antibodies, and observed that the only antibody which immunoprecipitated a type I receptor was the TP3RI antibody, ALK5 ( Fig. 4) . These data suggest that dnTP3RII-K277R can in fact associate with the type I TGFP3 receptor.
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Tf3RII /K277R ii) Impaired TGFP3-mediated Smad2 Phosphorylation in dnTP3RII-K277R Clones We next examined the effect of dnTP3RII-K277R expression on TGFP3-induced Smad2 phosphorylation. Immunoblot analysis of TGFP3 treated cell lysates using a phospho-specific Smad2 antibody revealed that while TGFP3 could induce phosphorylation of Smad2 in both GABE clones (G15-5 and G15-6), its ability to do so in the dnTP3RII-K277R clones was impaired ( Fig. 5 ). This impairment was not due to a decrease in total Smad2 protein, as reprobing with an antibody directed against the unphosphorylated form of Smad2 did not reveal any significant change in total Smad2 protein.
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Following phosphorylation, receptoractivated Smads associate with the common mediator Smad, Smad4, and translocate to the nucleus. Therefore, next we examined the effect ý1ll of dnTP3RII-K277R expression on TGFPinduced Smad translocation to the nucleus by immunofluorescence ( Fig. 6 ). In the GABE clone, in the absence of TGF]3, Smad2 staining was relatively diffuse, but upon TGFP3 treatment for 60 min, Smad2 staining became concentrated in the nucleus.
Nuclear localization of Smad2 was confirmed by staining the same cells with a nuclear dye. In Cells were grown on glass cover-slips for 24h, serum starved for 16h, contrast, in the dnTP3RII-K277R clones, there followed by treatment with 1 ng/ml TGFP31 for 60 min. Cells were then fixed, permeabilized, and blocked with 3% milk in PBS for indirect was little or no change in Smad2 staining immunofluorescence staining of Smad2 followed by nuclear staining following TGFP3 treatment, suggesting that with Hoechst. Cover-slips were mounted onto 25x75-mm microslides and fluorescent images were captured using a Princeton Instruments TGF[3-mediated translocation of Smad2 to the cooled CCD digital camera from a Zeiss Axiophot upright microscope. nucleus is impaired by dnTP3RII-K277R. iv) Impaired TGFP3-mediated Transcription in dnTP3RII-K277R Clones Following translocation to the nucleus, Smads regulate gene transcription, so we examined the effect of dnTP3RII-K277R expression on the ability of TGF[ to induce transcription of two TGF[ responsive reporter constructs, p3TP-luciferase, and pCAGA-luciferase. Each reporter construct was transiently transfected into the GABE and dnTP3Rll-K277R clones along with pCMV-Renilla, and luciferase activity before and after TGFP3 treatment was measured utilizing a dual luciferase reporter assay system. Normalized luciferase activity indicated that TGFP3 could induce transcription of both reporter constructs in the GABE clones (G15-5 and G15-6), but its ability to do so in the dnTI3RII-K277R clones was impaired ( Fig. 7) . Taken together, these data indicate that dnTf3RII-K277R is expressed and functional in MDA-MB-231 cells in that it can associate with TP3RI (ALK5), and block every step of TGFP3-mediated signal transduction examined, including Smad2 phosphorylation, translocation of Smad2 to the nucleus and transcription. This system was therefore used as a model to study the molecular mechanisms by which TGFP3 may be contributing to tumor maintenance and progression.
Although invasion and metastasis are complicated processes that involve multiple steps, active migration of cells into the surrounding tissue is a defining characteristic of the invasive tumor (Wells, 2000) . Thus, as an in vitro biological assay that may be relevant to the metastatic phenotype in vivo, we chose to examine the effect of dnT3RIH-K277R expression on the motility of MDA-MB-231cells in a wound closure assay. In this assay, a confluent monolayer of cells is wounded with a pipet tip, and the ability of the cells to migrate and close the wound is monitored by microscopy. In the GABE clones, complete wound closure was observed by 24h, while in the dnTP3RlI-K277R clones, although there was some closure, the wound remained open at 24h ( Fig. 8 ). This difference in motility did not appear to be due to an effect on proliferation because when the experiment was performed in the presence of mitomycin C, a were infected with adenoviruses encoding constitutively tip. Following wounding, cell culture medium was active mutants of the BMP (ALK2QD, ALK3QD) or TGFI3 replaced with fresh medium containing serum and (ALK5TD) type I receptors. Uninfected cells, and cells wound closure was monitored by microscopy at the infected with a P3-GAL adenovirus were used as controls. times indicated.
Following infection, cell monolayers were wounded with a pipet tip, and wound closure was monitored by microscopy at the times indicated.
compound that inhibits cell division, the same results were obtained. Thus, expression of dnT[3RII-K277R in MDA-MB-231 cells appears to impair their motility, independent of changes in proliferation.
Since we have data suggesting that in addition to blocking TGF[3 signaling, expression of dnT[3RII-K277R can also block BMP signaling in MDA-231 cells, we obtained adenoviruses encoding constitutively active mutants of TGFI3 and BMP type I receptors in order to assess the relative contribution of each pathway in motility. Our results indicate that the impairment in motility observed in our cells appears to be TGFI3 specific in that it could be restored by expression of a constitutively active type I TGF[3 receptor (ALK5TD), but not by constitutively active BMP type I receptors (ALK2 0 and ALK3 QD), Fig. 9 . Consistent with this, expression of Smad6, an inhibitory Smad which preferentially blocks BMP signaling, had no effect on the migration of parental or vector control cells in wound closure assays ( Fig. 10 ).
Effect of dnT/3RII-K2 77R Expression on MDA-231 Tumorigenesis and Metastasis
Tumor studies in nude mice were conducted in order to evaluate the effect of dnTI3RII-K277R expression on tumor formation and metastases in vivo. However, these experiments were not informative as the control cells expressing GFP alone, failed to form tumors. We suspect that there may have been some toxicity associated with the expression of GFP as parental cells not expressing GFP did form tumors Cells were infected with Smad6 or control ]3GAL encoding adenoviruses. Following infection, Smad6 expression was verified by immunoblot analysis utilizing an anti-FLAG antibody (A), and Smad6 function was evaluated by examining its ability to block BMP2-mediated Smadl phosphorylation (B). Despite being expressed and functional, Smad6 did not impair motility in wound closure assays (C).
following subcutaneous or orthotopic injections in nude mice. We have therefore generated additional stable cell lines expressing dnTf3RII-K277R without GFP, and are currently characterizing these for use in future in vivo studies.
Key Research Accomplishments
Generation and characterization of MDA-231 pools and clones stably expressing dnTP3RII-K277R or control vector with or without GFP. Motility is unaffected by expression of Smad6, an inhibitory Smad that preferentially blocks BMP signaling.
Since the dnTP3RII-K277R is expressed and functional in MDA-MB-231 breast cancer cells, this provides an excellent model in which to study the molecular mechanisms by which TGFO3 may contribute to tumor maintenance and progression. We have begun to do this utilizing migration as an in vitro biological assay that may provide insights into the mechanisms of invasion and metastasis. Biochemical experiments are currently underway to determine whether TGF[3-mediated motility is a Smad-dependent process that relies on changes in integrin expression and function. Identifying signal transducers involved in TGFP-mediated motility of breast cancer cells may provide important information for the selection of rational targets for therapeutic interventions. This may lead to opportunities to selectively inhibit the nondesirable tumor promoting effects of TGFP3 while retaining its tumor suppressive effects.
Like many cancers, colorectal cancer arises by metastasis. Numerous genes, including protoacquisition of genetic alterations that result in oncogenes, tumor suppressor genes, and DNA cellular transformation. Based on these alter-mismatch repair genes, have been implicated in ations, a genetic model for colorectal tumorig-the genesis of colon cancer. The discrete genetic enesis has been proposed (1). However, in ad-changes currently perceived as fundamental to dition to genetic changes, several epigenetic fac-the multistep process of colorectal tumorigentors have also been shown to contribute to the esis are illustrated in Fig. 1 . The tumorigenic development of colorectal cancer. This paper re-process is initiated when a cell of the normal views genetic as well as epigenetic contributions epithelium presumably undergoes a genetic to colorectal cancer, both of which present change that conveys a selective growth advanopportunities as potential therapeutic targets.
tage. This predisposes it to additional mutations, each of which confers further malignant potential, thereby leading to the clonal expan-GENETIC ABERRATIONS AND sion of this cell (1). Thus, neoplasms of the co-RELATED HISTOPATHOLOGICAL lon are clonal in nature in that they arise from FEATURES a single cell. Although sporadic mutations account for the majority of colorectal cancers, The development of colorectal cancer is a multi-there are two hereditary syndromes in which a step process involving a series of genetic strong tendency to develop colorectal cancer is changes in the colonic mucosa that lead sequen-transmitted by dominant inheritance: Familial tially to hyperplasia, adenoma, carcinoma, and Adenomatous Polyposis (FAP) and Hereditary Nonpolyposis Colorectal Cancer (HNPCC) (2) . by demonstrating cosegregation of mutant FAP is a syndrome in which an inherited defect APC alleles in affected kindreds (3, 4) . Howin the adenomatous polypOsis coli (APC) gene ever, the chromosome 5q region containing leads to the development of multiple benign pol-this gene is also frequently affected by loss of yps throughout the colon, some of which slowly heterozygosity (LOH) events in colorectal adprogress to invasive lesions. Thus, defects in enomas and carcinomas from patients without APC initiate the tumorigenic process, but ad-polyposis (5 7). In fact, over 70% of sporadic ditional mutations, such as those illustrated in colorectal cancers are believed to involve Fig. 1 , are required for tumor progression. In mutations in APC (8) . Studies have shown contrast to FAP, HNPCC is a syndrome char-that somatic mutations identified in sporadic acterized by the rapid progression of colorectal tumors are similar to those observed in the tumors due to inherited defects in DNA mis-germline of patients with FAP, often involving match repair (MMR) genes. Although the tu-codon 1309 located in the mutation cluster remors from patients with HNPCC go through a gion of the gene (9). These mutations have series of mutations similar to those described in been identified in adenomas as small as 5 mm, Fig. 1 , additional mutations, unique to consistent with the idea that mutations in the HNPCC, have been described. Evidence for the APC gene may be the initiating genetic event role of the genes most commonly implicated in in many tumors (7) . This is supported by the sporadic and hereditary colorectal tumors are fact that excision of adenomatous polyps sigdiscussed individually below.
nificantly reduces the incidence of cancer development (10) . Further support for the role APC of APC in the development of polyps and col-One of the earliest steps in the development orectal cancer stems from studies of a mouse of colorectal cancer is loss of function of the genetic model for FAP known as Min (for tumor suppressor gene, APC. This gene was multiple intestinal neoplasia). The Min mutafirst identified as the gene responsible for FAP tion, like those in many FAP patients, causes premature truncation of the APC protein, and K-ras mice heterozygous for the Min allele develop Although the three ras genes, K-ras, H-ras, multiple adenomatous polyps and cancers in and N-ras, are highly homologous, and believed their intestine (11) .
to be expressed at relatively equivalent levels in With respect to histopathological features, the colonic mucosa, only K-ras plays a signifi-APC mutations lead to dysplastic lesions affect-cant role in the development of colorectal caning the tube-shaped epithelial foldings of the co-cer. Mutations in K-ras can be identified in 50% lon referred to as crypts. Foci of dysplastic ab-of colorectal cancers (22), and occur most freerrant crypts are the earliest identifiable lesions quently in codon 12, with fewer mutations in colorectal tumorigenesis, and are believed to found at codons 13 and 61 (23) . Because K-ras be the precursors of adenomas (12) . In FAP pa-is an oncogene, mutation of one allele is enough tients, different types of APC mutations are as-to produce an effect. These mutations affect the sociated with different clinical features despite ability of p2lras to interact with the ras GTPathe fact that virtually all mutations result in C-se-activating protein, causing p2lras to remain terminally truncated APC proteins (2) . These in the active GTP-bound state. As a result, the differences are manifested primarily in extracogrowth and differentiation signal transduction Ionic sites, but may also be manifested by an pathways that include p21ras are constitutively attenuated form of FAP in which patients de-activated, leading to a continually growthvelop fewer polyps (13) . This phenotype is also stimulated state. observed in the Min mouse where, depending
The frequency of ras mutations appears to be on the inbred strain carrying the Min allele, correlated with two histopathological features: wide variations in polyp number are seen. Linkincreased tumor size and dysplasia. Studies have age analysis has demonstrated that much of the shown that 50% of adenomas greater than 1 cm variation is due to a single locus, named MOM-in diameter harbor K-ras mutations compared 1 (for modifier of Min) (14) , which encodes a to only 10% of adenomas less than 1 cm (22). secreted phospholipase A2 (15) .
When adenomas are distinguished from one an-Although the exact mechanism by which other with respect to the degree of dysplasia, APC mutations cause abnormal growth of col-ras mutations are more prevalent in tumors with orectal epithelial cells is not clear, the fact that increased dysplasia (24) . The higher prevalence the majority of somatic and germline mutations of ras mutations in later stage adenomas and in APC generate truncated APC proteins that carcinomas suggests that these mutations may lack a 3-catenin-binding domain suggests that arise in one cell of a small preexisting adenoma the interaction between APC and [-catenin may causing it to progress to a larger and more dysbe important (16) . Indeed, studies have shown plastic adenoma, with greater risk of subthat APC and glycogen synthase kinase 3 regu-sequent progression to cancer. This is consistent late cytoplasmic [-catenin levels by promoting with the fact that hyperplastic cells containing its degradation (17) . Inactivation of APC in colmutant ras genes, unlike their dysplastic orectal cells allows 03-catenin to accumulate and counterparts with mutant APC genes, have little complex with T-cell factor 4, leading to acti-or no potential to form clinically important tuvation of transcription and deregulated cell mors and may eventually regress through growth (18) . The importance of APC and [-catapoptosis (25) . enin in the development of colorectal cancer is further illustrated by the finding that 3-catenin DCC, Smad4, and the tumor suppressor activity is mutated in a subset of colorectal cancers that of the TGF-/ pathway lack somatic mutations in APC (19, 20) . In ad-LOH affecting the long arm of chromosome dition to its role in regulating P3-catenin, APC 18 can be detected in more than 70% of primary may also be involved in regulating apoptosis.
colorectal cancers, in about 50% of advanced Studies have shown that expression of wild-type adenomas, and infrequently in earlier stage ad-APC in colorectal epithelial cells with APC enomas, suggesting that loss in this region is a mutations results in cell death (21) . Thus, this relatively late event (22) . Such losses are also may be another mechanism by which inacticorrelated with greater mortality and increased vation of APC leads to deregulated cell growth.
propensity for metastatic spread (26, 27) . Ef-forts to identify a candidate tumor suppressor which have a phenotype similar to that of the gene from 18q led to the discovery of a gene Min mice, results in malignant progression of termed DCC (for deleted in colorectal cancer) the intestinal tumors at a much earlier stage (28) . The DCC gene encodes a transmembrane than that observed in the simple APCA 7 16 protein of the immunoglobulin superfamily. The knockout mice (38) . Mice heterozygous only for predicted structural similarity of DCC to the N-the Snmad4 knockout show no apparent tumor CAM family of cell-surface adhesion molecules phenotype, indicating that the Smad4 gene is a suggested that it might function in differen-suppressor of tumor progression, but not of tutiation pathways and cell fate determination mor initiation (38) . The fact that inactivation through cell-cell and/or cell-extracellular matrix of Srnad4 in APCA 7 1 6 knockout mice enhances interactions (29) . Therefore, it was hypothesized tumor progression, while inactivation of DCC that loss of cell-cell contact might explain the in a similar mouse model does not, suggests that enhanced metastasis observed in patients with the tumor suppressor gene associated with LOH loss of DCC (29) . However, more recent studies on 18q21 is more likely to be Smad4. In support have shown that inactivation of the murine of this, mutations in the Smad4 gene have been DCC gene does not affect the proliferation or identified in human colorectal cancers in vivo differentiation of intestinal epithelial cells, nor (33, 39, 40) , and in familial juvenile polyposis, does it affect the morphogenesis of colonic which, like FAP, is a syndrome characterized by crypts and villi (30) . Moreover, introduction of a predisposition to hemartomatous polyps and the null DCC allele into the germ line of the gastrointestinal cancer (41) .
Min mouse does not accelerate the progression
A role for Smad4 in the malignant proof, or modify the phenotype of polyps initiated gression of colorectal tumors is consistent with in the Min mice (30) . Instead, the phenotype of previous findings that have implicated other mice lacking a functional DCC gene resembles members of the TGF-P3 pathway in colorectal that of netrin-l-deficient mice, with defects in tumorigenesis (summarized in Fig. 2 ). For exaxonal projections and brain development (30) .
ample, as previously mentioned, Srnad2 is a can-These findings fail to support a tumor sup-didate tumor suppressor gene also located on pressor function for DCC in the development 18q21. Inactivating missense mutations and deof colorectal cancer, and are inconsistent with letions of the Smad2 gene have been detected studies in which reduction or loss of DCC RNA in sporadic colorectal carcinomas (32, 42) . In has been observed in cell lines or xenografts de-addition to Smad2 and Smad4, Smad3 is anrived from human colon carcinomas (28, 31) .
other member of the SMAD family of proteins The discrepancy between these results may be involved in mediating TGF-P3 signaling. Aldue to differences in the pathogenesis of col-though mutations in the Smad3 gene have not orectal cancer between mice and humans. Alter-yet been detected in human colorectal cancer natively, LOH of 18q21 may not only affect the (43, 44) , LOH of Smad3 has been detected in 2 DCC gene, but neighboring genes as well, one
(1 sporadic and 1 HNPCC) of 17 colorectal canor more of which may be the target of inacti-cers examined (44) , and a recent study has revation during colon tumor progression (30) . In-ported that inactivation of the Srnad3 gene in deed, other candidate tumor suppressor genes, mice leads to the development of metastatic colincluding Smad2 and Smad4, have been iden-orectal cancer (45) . Upstream of the SMAD sigtified on chromosome 18q21 (32, 33) . Both naling proteins, mutations in the TGF-P3 type II Smad2 and Smnad4 belong to the SMAD gene receptor (TGF-P3RII) have been associated with family involved in the signal transduction path-microsatellite instability in both colon cancers ways activated through the TGF-f3 family of re-and colorectal carcinoma cell lines (46) (47) (48) . Resceptors (34). The TGF-13s are important regu-toration of TGF-I3RII expression by gene translators of cell growth and differentiation (35) . fection has been found to reverse the transform-Escape from the growth regulatory effects of ed phenotype (49) . There is also evidence that TGF-P3s is common among many different can-transfection of TGF-P3-responsive human colon cers (35, 36) , including colorectal cancer (37) . carcinoma cells with a TGF-031 antisense ex-Recent studies have shown that inactivation of pression vector increases their tumorigenicity the Smad4 gene in APCA 7 1 6 knockout mice, (50) . These data taken together highlight the im-714 portance of the TGF-03 signaling pathway in much less frequent in earlier stages of carcinoregulating the progression of colorectal cancer. genesis, and rare in both adenomas and polyps (22) . Moreover, patients with germline muta-p53 tions in p53 do not develop polyposis, nor are The chromosomal region most frequently they at risk for developing colorectal cancer affected by LOH in colorectal cancers is 17p (54) . This suggests that, although p53 plays an (51), a region which includes the tumor sup-important role in colorectal carcinogenesis, unpressor gene, p53. Sequence analysis of the re-like APC it cannot initiate the process. Likemaining p53 allele from a large number of col-wise, p53-deficient mice are prone to develop orectal carcinomas in which 17p was affected cancers, but an initiating event is required for by LOH revealed that missense mutations were tumor development (55, 56) . Moreover, the incipresent in over 80% of the cases (52, 53) , indi-dence of colorectal cancer in these animals is cating that loss of p53 function is an important low, indicating that loss of p53 function alone step in the development of colorectal cancer. Al-does not cause transformation (57) . This is conthough p53 mutations are extremely prevalent sistent with the role of p53 as a cell-cycle checkin many advanced colorectal cancers, they are point regulator (58) . Abrogation of either p53- (71) (72) (73) (74) , are associated with extracellular allow cells that have incurred mutations and are mucin production (73), poor differentiation not fit to progress through the cell cycle to do (71) (72) (73) , and diploidy (69, 72) . In addition, they so anyway, resulting in tumor progression, are less likely to have LOH at known tumor With respect to clinical features, the presence suppressor gene loci on chromosomes 5q, 18q, of mutant p53, as determined by increased im-and 17p (74) . On the other hand, inactivation of munohistochemical staining or by analysis of TGF-[3RII due to frameshift mutations within gene sequence, is correlated with poor survival, coding microsatellite sequences occurs freas well as increased cancer recurrence rates (59, quently (47, 48) . Although defects in the same 60).
MMR genes that are affected in HNPCC have been identified in sporadic colorectal cancers MMR genes with microsatellite instability (75), substantial DNA mismatch repair plays a prominent role differences in the nature and incidence of these in the correction of replicative mismatches mutations have been reported, suggesting that which escape DNA polymerase proofreading.
the molecular mechanisms underlying insta-Three genes, MutS, MutL, and MutH, are cen-bility in the sporadic cases differ from those in tral to the correction of replication errors in E.
HNPCC (2, 76) . However, mutations in hMSH3 coli (61) . In humans, germline mutations in the and hMSH6, two other MutS genes initially MutS homologue, hMSH2 (62, 63) , or in any of identified in sporadic colorectal tumors with the three MutL homologues, hMLH1, hPMSI, microsatellite instability (77, 78) , have recently and hPMS2 (64-66), have been identified as been reported in HNPCC patients. This sugbeing responsible for HNPCC. These reports gests that the molecular mechanisms underlying suggest that mutations in hMSH2 and hMLH1 instability may be similar in tumors with microtogether account for the majority of HNPCC, satellite instability regardless of their sporadic while mutations in hPMS1 and hPMS2 are less or hereditary nature (79) . frequently observed. A characteristic feature of tumors arising in individuals with HNPCC is the presence of microsatellite instability. Micro-EPIGENETIC FACTORS THAT satellites are regions consisting of single, dinu-CONTRIBUTE TO COLORECTAL cleotide, or trinucleotide repeats that are widely CANCER distributed throughout the genome. These sequences are prone to replication errors due to Age and diet. Consistent with the multi-hit their repetitive structure, which favors slippage hypothesis for the development of cancer, the during replication. Thus, when MMR genes are incidence of colorectal cancer increases with mutated, errors arising during DNA replication age, as greater numbers of mutations are acare less efficiently corrected, resulting in a cumulated with time (80, 81) . Although genreplication error-prone (RER+) phenotype. etic aberrations and hereditary disorders play Affected cells accumulate errors (mutations) at a critical role in the development of colorectal a much greater rate than normal cells (67). This cancers (section above), the fact that the inciis manifested clinically by a much faster pro-dence varies tremendously according to gegression of the disease. In contrast to sporadic ography suggests that other factors must also colorectal cancers, which may take 10 to 15 be involved (82) . One of the major differences years to develop, patients with HNPCC have in lifestyle between cultures (which may exbeen found to develop cancers within 2 years plain geographic differences in colorectal canafter a normal colonoscopy (68) . cer incidence) is diet (83) . A number of die-Microsatellite instability is not only a charac-tary components have been implicated as teristic feature of HNPCC tumors, it is also ob-possible factors in the development of colorecserved in a subset (about 17%) of sporadic col-tal cancer. The major factors include overall orectal cancers (69) (70) (71) (72) (73) . Sporadic tumors with caloric intake, fat content of the diet, and fibmicrosatellite instability share common clinical er intake. The number of calories consumed and histopathological features with HNPCC tu-per day and the fat content in the diet have mors. They are usually located in the proximal been consistently positively correlated with the risk of developing colorectal cancer (80) . The Angiogenesis is not only essential for the exmechanism by which a high-fat diet enhances pansion of the primary tumor, it is also retumor formation may be related to high fecal quired for the establishment and growth of bile acid levels which stimulate mucosal epi-metastases at distant sites. In fact, there is evithelial proliferation. In contrast, vegetable and dence that systemic suppression of angiogenfiber consumption seem to have a protective esis can maintain micrometastases dormant as effect (84, 85) . Fiber may work either by ina result of a balance between proliferation and creasing the stool transit time and thereby de-apoptosis (94) . Therefore, the degree of angiocreasing contact with fecal contents, by bind-genesis may be an important factor in detering luminal toxic compounds, or by providing mining tumor behavior and the propensity to fuel for colonic bacteria that produce short-metastasize. Indeed, in patients with colorectal chain fatty acids that may inhibit proliferation cancer, angiogenesis has been correlated with and promote apoptosis (86) . Consistent with a higher recurrence rate and diminished surthe protective effects of dietary fiber, the invival (95) . take of selenium, an essential trace mineral Immune response. Another epigenetic factor found in cereal grains, has also been found to important in the development of colorectal canbe inversely correlated with the incidence of cer is ineffective immune response. Unlike colorectal cancer (87-89). Since selenium is a virally or chemically induced tumors, sponcofactor for glutathione peroxidase, which taneous tumors, such as those arising in the coparticipates in preventing free radical damage lon, elicit a weak immune response. Although to tissues, part of selenium's protective effect mutant proteins encoded by oncogenes (K-ras) may be due to a reduction in free radical or tumor suppressor genes (APC, DCC, Smad4, damage.
Smad2, tgf-/3RII, tgf-/l3, p53) that have under-Angiogenesis. In addition to the risk factors gone mutations can be recognized as tumor-speassociated with lifestyle, physiological processes cific antigens, their recognition delivers only one such as angiogenesis also contribute to the of the two signals required for T-cell-mediated pathogenesis of colorectal cancer. Studies have immunity. This is due to the fact that very few shown that in order for a tumor to grow beyond professional antigen-presenting cells (dendritic a few millimeters in diameter, the formation of cells, macrophages, and B-cells) are present in new blood vessels is required to provide nutricolorectal tumors (96) . Thus, most of the muents and a means of eliminating metabolic waste tant proteins are processed and presented as products (90) . As tumors get larger, the center antigenic peptides bound to class I MHC on the of the tumor often becomes hypoxic due to in-surface of colon cancer cells. Since these cells adequate vascularization, leading to cell death are not professional antigen-presenting cells, within the hypoxic center. Because hypoxia can they lack the costimulatory signal (B7) that induce apoptosis in a p53-dependent manner must be recognized by T-cells in order to elicit (91), low oxygen conditions can provide a selec-an immune response. Recognition of foreign tive advantage for cells carrying mutations in antigen in the absence of a costimulatory signal p53, allowing escape from apoptosis. This may leads to T-cell anergy. Consequently, although a be particularly important in colorectal cancer large number of T-lymphocytes have been idenbecause p53 mutations are prevalent, and occur tified in primary colorectal tumors (97), T-celllate in the adenoma-carcinoma sequence. Thus, mediated immunity is ineffective in eliminating by escaping apoptosis, tumor cells bearing p53 tumor cells. In contrast, natural killer cells have mutations within a colorectal carcinoma retain a spontaneous cytotoxic capacity against tumor their proliferative capacity, thereby promoting cells. However, these cells are either not found tumor expansion. In addition, since p53 ex-or are only present in low numbers in colorectal pression results in the secretion of inhibitors of cancers (96, 98) . In addition, studies have angiogenesis (92, 93) , selection of p53 mutations shown that MHC expression on professional by hypoxic conditions could lead to loss of ex-antigen-presenting cells within colorectal tupression of antiangiogenic factors, allowing mors is often lost, thereby further comprogrowth of new blood vessels, thereby favoring mising immunity against tumors (99) . further expansion of the tumor.
Related to immune function, epidemio-logical studies have shown that chronic use of CONCLUSION aspirin results in a reduced risk of colorectal cancer (100) , and that treatment of FAP pa-Since many genetic aberrations contribute to tients with non-steroidal anti-inflammatory the development of colorectal cancer, each drugs (NSAIDs) results in regression of rectal affected gene could potentially be a good therapolyps (101) . These studies suggest that in-peutic target. Identification of these genetic abflammation may contribute to the develop-errations has provided an opportunity to use ment of colorectal cancer. NSAIDs mediate different strategies to deliver normal copies of their effects by inhibiting two enzymes, COX-defective tumor suppressor genes to affected I and COX-2, which are responsible for eicos-tissues, or to inactivate oncogenes. Although anoid synthesis. Analysis of COX-2 mRNA in these avenues hold promise, not all of the gencolon cancers and adenomatous polyps re-etic aberrations described above occur in all invealed increases of 86% and 43%, respectively, dividuals with colorectal cancer. In contrast, compared to in normal mucosa from the same epigenetic factors do indeed contribute to the patients (102). Consistent with elevated COX-development of all colorectal tumors and there-2 levels, prostaglandin E2 levels have also been by provide additional opportunities for interfound to be elevated in colon cancers and pol-vention. Therapies targeting both genetic and yps (103, 104). Further support for the role of epigenetic aberrations could be combined to COX-2 in the development of colorectal cancer provide a broader and more effective therapy has been obtained using an APC knockout for patients. mouse with a phenotype similar to that of the Min mouse. Inactivation of the COX-2 gene in I would like to thank Dr. Lynn Matrisian for critithese mice resulted in an 86% decrease in in-cally reviewing this manuscript and Dr. Anne Lenfertestinal and colonic polyps compared to con-ink for her assistance in preparing the figures. This work is supported in part by a U.S. Army Breast trol animals (105). In addition, when animals Cancer Pre-doctoral Training Award. heterozygous for APC, but having normal COX-2, were treated with a novel specific inhibitor of COX-2 enzyme activity, polyp num-REFERENCES bers decreased by 50-60% compared to a 26% decrease when they were treated with the I. Introduction biphasic: TGF-31 acts early as a tumor suppressor, proba-Although the transforming growth factor (TGF)-ps can be bly by inhibiting the proliferation of nontransformed cells, tumor suppressive [1], there is increasing evidence that and it acts later as a tumor promoter by eliciting an epithe-TGF-P secretion by tumor cells and/or stromal cells within lial-to-mesenchymal transition (EMT). Additional experithe peritumoral microenvironment can contribute to tumor ments have suggested that upregulation of TGF-P3 in the maintenance and progression. How, then, can TGF-ps be spindle carcinomas was responsible for maintenance of both tumor suppressive and tumor promoting? This appar-this invasive phenotype [2"°] . This is consistent with ent paradox is reconciled by a study showing that, in a TGF-P3 expression at sites in mouse embryos where mouse skin model of chemical carcinogenesis, targeted epithelial-mesenchymal interactions are important, like the expression of TGF-I1 in suprabasal keratinocytes appears lung and palatal shelves [3, 4] , and also the abnormal lung to have dual effects. It suppresses the formation of benign development and cleft palate observed in TGF-03 null skin tumors, but once tumors develop, it enhances their mice [5] . Also consistent with an early tumor suppressive progression to a highly invasive spindle cell phenotype effect is the recent observation that tgf-pl-/-mice develop the tumorigenesis of Ha-Ras mammary cells, introduction sion of the antagonistic Smad, Smad7, in pancreatic carci-of dominant negative TPRII into these cells retarded tumor noma cell lines not only suppresses TGF-131-mediated formation and prevented EMT in vivo; moreover, introducgrowth inhibition, but enhances the ability of TGF-j1 to tion of the same construct into highly invasive murine induce matrix associated transcriptional responses [7] . colon carcinoma cells reconstituted an epithelial phenotype in vitro, and inhibited both tumor outgrowth and the The progression of epithelial tumors to an invasive establishment of metastases [20] . In colon cancer cells of metastatic state is often associated with EMT, downregu-low invasive potential and with naturally occurring mutalation of cellular adhesion molecules, elevated expression tions in the T3RII gene, re-expression of TI3RII function of metalloproteases, and increased motility and angiogen-restored tumor cell invasiveness [20' ]. In another study, esis, all of which can be modulated by TGF-js. It is there-expression of dominant negative TPRII in clones derived fore not surprising that the TGF-3s can also promote from a metastatic squamous carcinoma cell line prevented tumorigenesis by modulating these critical processes. In their spontaneous progression to a spindle phenotype in support of this view, elevated levels of TGF-3 are often vivo [21] . Furthermore, approximately 900/0 of colon observed in advanced carcinomas, and have been corre-cancers with microsatellite instability have inactivating lated with disease progression in several studies [8-131. mutations of TPRII [33] , and this instability is significantly This suggests that secreting higher levels of TGF-3 may correlated with longer patient survival [34], suggesting provide an advantage to tumor cells. Both autocrine and that complete loss of TP3RII in carcinomas may limit sysparacrine signaling may be involved in conferring this temic metastases. Taken together, these results suggest selective advantage. While mutations in various compo-that EMT, local tumor growth, and metastatic progression nents of the TGF-j signaling pathway have been observed can be sustained by autocrine TGF-P signaling. in some carcinomas, particularly colorectal cancers [14, 15] , an intact TGF-3 signaling pathway is often When tumors are grown in nude mice, TGF-p3s made by retained in other malignancies as some tumors can exhibit host cells can induce responses in tumor cells with intact increased invasiveness in response to exogenous TGF-P3 TGF-P signaling, with the net effect of these tumor-host [16,117,18,19,20*,21] . Moreover, in a recent study of a interactions being deleterious to the host. For example, large cohort of human breast tumors, loss or low levels of MDA-231 human breast tumor cells secrete parathyroid the type II TGF-P receptor (TPRII) correlated with high hormone-related protein (PTHrP) in response to exogetumor grade, but 600/% of in situ and invasive breast carci-nous TGF-pI, metastasize to bone when injected into nomas retained robust levels of TPRII expression by nude mice, and induce osteolysis and hypercalcemia, immunohistochemistry [22] . Finally, although Smad4 is fre-resulting in host death. Transfection of these cells with quently inactivated in pancreatic cancers [23, 24] , the dominant negative Tf3RII blocks TGF-131 -mediated stimula-Smad genes, which encode proteins that transduce tion of PTHrP production. Mice injected with these cells TGF-3 signals, are rarely mutated in most human carcino-exhibited less osteolysis, higher body weight, lower serum mas [25] [26] [27] [28] [29] [30] . This suggests that after cells lose their sen-calcium and PTHrP levels, and longer survival than mice sitivity to TGF-P growth inhibition, autocrine TGF-P injected with control MDA-231 cells [351] . On the consignaling may potentially promote tumor progression. In trary, accelerated osteolysis and reduced host survival addition, TGF-ps produced in excess by tumor cells may were observed when mice where injected with tumor cells act in a paracrine fashion on the peritumoral stroma, tumor transfected with a constitutively active TI3RI, suggesting a neovessels, or the immune system, indirectly fostering possible role for TGF-p-mediated responses in the pathotumor progression, genesis of some adverse paraneoplastic syndromes.
Autocrine effects
Several recent studies have contributed to our understand-Epithelial-to-mesenchymal transition ing of the biochemical mechanisms by which transformed Similar to keratinocytes [2-1, TGF-31 can also induce a cells can lose autocrine growth inhibition but retain TGF-Prapid and reversible EMT in melanoma cells [31] , and in mediated responses that contribute to tumor progression. both nontumor [32] and Ha-Ras transformed [17°]
For example, oncogenic activation of the Ras pathway, mammary epithelial cells in vitro. In Ha-Ras mammary acting via MAP kinases, causes phosphorylation of Smad2 tumors, EMT appears to be initiated by TGF-13 produced and Smad3 at specific Erk consensus sites in the linker by peritumoral host cells and later maintained by autocrine region between their DNA binding and transcriptional TGF-P1 as the converted tumor cells themselves begin to activation domains. This results in loss of nuclear accumu-126
secrete TGF-pl. The Ha-Ras tumor cells obtained after lation of Smad2/3 and silencing of TGF-p-mediated http ://breast-cancer-research.com/content/2/2/1 25 antiproliferative responses [36°*]. In nontransformed Increased motility mammary cells, introduction of mutant Ras not only blocks TGF-P can stimulate the motility of many cell types in vitro growth inhibition by TGF-13, but also subverts this pathway [43] [44] [45] , therefore suggesting that TGF-P production in into one that can stimulate epithelial-to-mesenchymal vivo may enhance migration of tumor cells and metastatic transdifferentiation [117,20*]. In MDCK epithelial cells, potential. Indeed, cyclosporine treatment of lung adenotransfection of the missense mutations Smad2.D450E carcinoma cells results in increased cell motility and and Smad2.P445H, reported in primary colorectal and anchorage independent growth in vitro, as well as lung carcinomas, does not abolish TGF-f-mediated growth increased metastases in vivo, all of which can be blocked arrest. Instead, it increases both basal and TGF-3 stimu-with neutralizing TGF-P1 antibodies [46] . These results lated invasiveness, neither of which is prevented by overex-suggest that in vivo tumor progression by cyclosporine is pression of the inhibitory Smad7 [37°]. This suggests the dependent on autocrine TGF-P1. In prostate cancer cells, existence of Smad 'gain-of-function' mutations that TGF-131 stimulates motility without affecting cell proliferaenhance malignant progression by mechanisms indepen-tion, suggesting that the effects on motility and proliferadent of TPRI and Smad phosphorylation. Another study has tion may occur via different biochemical pathways [43] . shown that Smad7 mRNA levels are increased in human pancreatic cancers compared with normal pancreas [7°].
Whether blockade of the Smad pathway, critical for Stable transfection of COLO-357 human pancreatic TGF-13-mediated antimitogenic effects [47, 48] , is also cancer cells with a Smad7 expression vector results in loss critical for the effects of TGF-Ps on cell motility is not of TGF-P1 -mediated growth inhibition and p21/Cipl pro-clear. Some evidence suggests that the latter may follow moter activity. However, TGF-jl-induced plasminogen alternative signaling pathways, perhaps in cooperation activator inhibitor-1 (PAl-l) promoter activity is maintained with activated oncogenes. Atfi et al [49] reported and, more importantly, basal PAl-1 promoter activity, PAl-1 recently that inactivating components of the JNK mRNA levels, anchorage independent colony growth, and pathway, which regulates AP-1 activity via c-Jun, inhibits tumorigenicity in nude mice, are all increased in the Smad7 TGF-p3-mediated induction of 3TP-Lux, a reporter contransfected clones [7] . This result suggests another poten-struct that contains Smad and AP-1 binding elements. tial mechanism, the overexpression of Smad7, for the seg-Dominant negative mutants of RhoA, Racl, and Cdc42, regation between antiproliferative and matrix associated GTPases that mediate cell shape, cytoskeletal organiza-TGF-P responses. In addition, overexpression of Smad4 in tion, and motility, abolish TGF-13-mediated transcription colon carcinoma cells does not reconstitute TGF-3-medi-of AP-1 [49, 50] , suggesting that the Rho family of ated antiproliferative responses [38°, 39] , but inhibits cell GTPases and the JNK pathway are essential compoadhesion and spreading, reduces the levels of urokinase nents of TGF-P signaling responses. TGF-P1 can also plasminogen activator and PAl-l, and prolongs tumor upregulate integrin linked kinase [31] , a protein associlatency [39] , suggesting an additional function for Smad4 ated with fibronectin production and increased cell motilin restraining genes involved in peritumor proteolysis and ity. In another study, TGF-P1 treatment of NMuMG invasion. This is further supported by reports of homozy-mouse mammary epithelial cells increased the expresgous deletion of T/3RI or homozygous missense mutations sion of N-cadherin [51] , which has been shown to of T/3RII [40, 41] , each coexisting with deletions of Smad4 increase motility of squamous cancer cells [52] . in individual tumors. The coexistence of these mutations in the same tumors would not be expected if the function of Paracrine effects these two gene products (TPRII and Smad4 or TPRI and Induction of metalloproteases Smad4) was limited to a single common signal transduc-Matrix metalloproteases (MMPs) play a critical role in the tion pathway. Taken together, these studies suggest, first, proteolytic degradation of basement membrane that is that the threshold for loss of TGF-P antimitogenic effects is required for tumor invasion [53] . The expression of several lower than that required to lose responses associated with MMPs, including MMP-2 [54] and MMP-9 [18, 31, 55] , can cell adhesion, invasion, and metastases; second, that not be induced by TGF-3. Moreover, TGF-P1 has been shown one but multiple biochemical mechanisms can contribute to selectively induce MMP-9 activity in a subset of to the enhancement or unmasking of the tumor promoting metastatic but not primary mouse prostate tumors, implyeffects of autocrine TGF-P; and, third, that some of these ing that this TGF-P1 -induced response may be an impormechanisms may be independent of Smad function or TPRI tant selection step in tumor progression [118] . There is also phosphorylation. The identification of Smad dependent and evidence that TGF-13 increases MT-MMP-1 and MMP-9 independent genes causally involved in these TGF-P-medi-expression in metastatic melanoma [31] . Tumor angiogenesis body that blocks TGF-31, TGF-P2, and TGF-P3 has been It is generally accepted that solid tumors require an adeshown to suppress the growth of TGF-pl-overexpressing quate blood supply in order to grow beyond a few milli-renal cancer xenografts [70] . In this study, the TGF-P meters in size. TGF-3s, particularly TGF-P1, have been blocking monoclonal-abrogated factor VIII staining in the shown to regulate new blood vessel formation both in vitro xenografts, suggesting an antitumor mechanism that and in vivo by a combination of responses that include targets endothelial cells [70] . Furthermore, TGF-P1 and increased production and facilitation of vascular endothe-PAl-1 have been shown to inhibit the conversion of plaslial growth factor, facilitation of basic fibroblast growth minogen to the anti-angiogenic molecule angiostatin in factor mediated capillary sprouting, inhibition of endothe-medium conditioned by human pancreatic cancer cells lial cell migration, and increased production of extracellular [71] . This suggests an additional pro-angiogenic mechamatrix, among others (reviewed in [57] ). In most cells, nism for TGF-3 by interfering with the production of T3RI/ALK-5 is the signaling receptor for TGF-P3. However, endogenous inhibitors of endothelial cell proliferation. in endothelial cells, it has been suggested that ALK-1 may Finally, high levels of TGF-P1 mRNA correlate strongly with also function as a type I receptor for TGF-13 [58] . In addi-high microvessel density in breast tumors, and each of tion to the type 1, 11, and III TGF-3 receptors, endoglin is these factors is associated with poor patient outcome [721. another integral membrane protein that binds TGF-31 and TGF-P33, and is highly expressed in endothelial cells [591.
Host immunosuppression Although TGF-3 effects appear to be mediated mostly by TGF-P1 and TGF-P2 are potent immunosuppressants the receptor specific Smad2 and Smad3 proteins [47, 48] , [73] . Thus, elevated levels of TGF-js secreted by tumors there is evidence that Smad5 is involved in TGF-3 signal-could potentially inhibit immune effector cells and favor ing in hematopoietic cells [60] . Targeted disruption of tumor progression. In support of this idea, Torre Amione et genes encoding various components of the TGF-P signal-al [74] demonstrated that, unlike parental tumor cells, ing pathway, including TGF-P31 itself [61] , its receptors, fibrosarcoma cells transfected to express 10ng/ml TPRII [621, ALK-1 [63] , and endoglin [64] , and one of its TGF-131 in vitro are unable to induce cytotoxic T lymphosignal transducers, Smad5 [65] , has each revealed that cyte (CTL) responses and can escape immune recognithese proteins play an important role in vascular develop-tion. Likewise, EMT6 mammary tumor cells, which ment. The phenotype of the TGF-31 and TPRII knockout produce high levels of TGF-P1, can inhibit CTLs in vivo. mice is virtually indistinguishable and is characterized by Transfection of these cells with interleukin-2, a known defective endothelial differentiation resulting in abnormal T cell growth factor, can reverse this TGF-P1 effect and capillary tube formation [61, 62] . In contrast, disruption of induce tumor rejection [75] . This result suggests that, by ALK-1, endoglin, or Smad5 does not affect endothelial dif-dampening the generation of tumor reactive T cells, TGF-3 ferentiation or vasculogenesis, but instead they each can promote tumor viability. There is also evidence that affect angiogenesis. In addition, endoglin-I-and overexpression of the soluble TP3RII extracellular domain in Smad5-/-mice exhibit impaired vascular smooth muscle thymoma cells can prevent the progression of unmodified cell development. These results are consistent with previ-thymoma cells when injected near the primary tumor inocous reports demonstrating that TGF-3 can regulate ulation site [76] , further suggesting that secretion of smooth muscle cell differentiation and migration in vitro soluble TPRII by these cells is sufficient to restore tumor [66"], thus contributing to pericyte recruitment and vessel specific cellular immunity and mediate partial tumor rejecstabilization. This hypothesis, as it applies to tumor angio-tion. Overall, these results are consistent with the phenogenesis, is somewhat challenged by the notion that the type of TGF-/31 null mice that die shortly after birth as a majority of intratumoral neovessels seem to lack perien-result of widespread inflammation and multiorgan T cell dothelial smooth muscle cells [67] , suggesting that there infiltration and necrosis [77] . may be additional roles for the TGF-Ps in tumor angiogenesis. In that light, Higaki and Shimokado [68] recently
In addition to inhibiting CTL responses, TGF-Ps can modreported TGF-1l-mediated stimulation of phosphatidyli-ulate other immune functions that may favor tumor pronositol-3 kinase activity and amino acid uptake in vascular gression. For example, CHO cells transfected with an smooth muscle cells, suggesting a direct anti-apoptotic expression vector encoding latent TGF-PI, when injected role for TGF-13. Elucidation of the paracrine mechanisms into nude mice, can decrease mouse spleen natural killer driving TGF-3-mediated tumor angiogenesis requires activity and rapidly form tumors [78] . Antagonizing TGF-js further investigation.
by intraperitoneal injection of an antibody that neutralizes TGF-I31, TGF-P2, and TGF-P3 has the opposite effect. It Further supporting the role of TGF-P3s in tumor angiogene-prevents tumor and metastases formation by MDA-231 sis, administration of a neutralizing TGF-P1 antibody to human breast carcinoma cells, and markedly increases nude mice harboring CHO cell xenografts transfected with natural killer activity of mouse splenocytes [79] . Consisectopic TGF-P31 inhibits both tumor growth and intratumor tent with this TGF-p-mediated immunosuppressive effect, 128 microvessel density [691. In addition, a monoclonal antireduced immune function has been observed in animals http://breast-cancer-research.com/content/2/2/1 25 bearing TGF-P overexpressing tumors [80] as well as in spare the tumor host from undue toxicity. Several patients with glioblastoma, a common type of brain tumor approaches have been proposed, including the use of that frequently overexpresses TGF-P2 [81] .
blocking antibodies against TGF-Pl, TGF-P2, and TGF-33, using the soluble ectodomains of the type II The cited studies suggest that tumor cell secreted TGF-Ps and III TGF-P receptors, which would sequester TGF-P3 may block the efferent function of immune effectors at isoforms at tumor sites and prevent binding to cognate sites of tumor implantation. Other reports, however, receptors [87, 88] , and, finally, using adenovirus encoding suggest tumor cell TGF-Ps may modify the afferent cominhibitors of TGF-P signaling [89] , to name a few. The ponent of the immune response and confer antitumor theoretical and logistical strengths and limitations of these immunity. Stable infection of breast and glioma tumor cells approaches are beyond the scope of this review. Nonethewith antisense TGF-f31 and antisense TGF-P2 retroless, these represent tools that, if effective in blocking viruses, respectively, has been shown to restore the TGF-3 action, will allow us to address the net effect of immunogenicity of these tumor cells when injected into autocrine/paracrine TGF-P signaling at early and late immunocompetent animals. Furthermore, they induce a stages of transformation and cancer progression. partial rejection of unmodified, less immunogenic established wild type tumor cells [82, 83] . In both of these References studies, in vitro and in vivo CTL activity was markedly 
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Migration Invasion ically, no discernible differences in the morphology or local invasiveness of the primary tumors were observed among the test and control groups. All primary tumors were well demarcated and scriptional activation by TGF-P in the majority of clones tested extended from the epidermal/dermal junction through the dermis (Fig. 7) . Additionally, the expression of DNRII resulted in a with infiltration into the abdominal musculature. Each tumor was decrease of TGF-p3-induced phosphorylation of Smad2 (Fig. 7b) . bordered by mild neutrophilic inflammatory infiltrates and con-Furthermore, when injected orthotopically into the mammary tained extensive necrotic foci. Carcinoma cells were not observed gland of immunodeficient SCID mice, 3 of the 4 clones expressing in blood vessels adjacent to the primary tumors. In contrast to the the DNRII were severely inhibited in their ability to form meta-effects on in vivo metastasis, the expression of the truncated static lung nodules (Table I) . Approximately 114 ± 35 (n=4) TGF-P3 type II receptor did not affect in vitro migration and metastatic nodules were found in the lungs of mice that were invasion (data not shown). orthotopically injected with mock-transfected 4T1 cells (4TlZeo) compared with 15.5 +_ 6.5 (n= 15) in mice injected with DNRIIexpressing tumor cells. In the majority of mice injected with gene-modified tumor cells, the sizes of the primary tumors were
In our study we investigated the role of TGF-[3 in the metastatic not significantly different from those in control animals injected phenotype ofa highly metastatic murine 4T1 mammary tumor. We with tumor cells transfected with vector alone (Table I) 3 -± 1 calization of E-cadherin, changes frequently associated with the 'SCID mice were injected orthotopically with parental, mock trans-invasive and metastatic phenotype'4,t'. Similar Smad-dependent fected or gene-modified 4T1 cells. Three weeks post-injection, the pathways present in 4T1 tumor cells may contribute to their mice were sacrificed and their lungs were collected and examined for invasive and metastatic activities. That 4T1 cells secrete TGF-[3 the presence of surface metastases. Values represent the mean ± and exhibit basal levels of Smad2 phosphorylation suggests a cell standard error (n = 4).
autonomous mechanism of TGF-[3 signaling which may contribute to the metastatic phenotype as has been proposed in murine models of renal, lung, mammary and colon cancers. 1 4 ,17,1 9 Experiments are invade and metastasize in vivo. The results also exhibit that 4T1 in progress to resolve this question. cells are resistant to TGF-p3-mediated growth inhibition yet re-
The importance of TGF-[3 in the invasion and metastasis of 4T1 spond to TGF-13 as demonstrated by the presence of membrane tumor cells was demonstrated in studies in which expression of a receptors that bind ligand, initiate downstream phosphorylation of truncated dominant negative receptor significantly suppressed for-Smad2 and induce Smad-dependent transcriptional activation. mation of lung metastases in vivo. Whereas metastasis formation Thus, unlike numerous cancer cells whose resistance to TGF-P3 was severely curbed, tumorigenicity at the primary tumor injection growth inhibition is due to inactivation of TGF-[3 receptors 29 -3 ' or site was not affected. This observation is in agreement with that of Smad family signal transducers, 32 4T 1 cells are capable of TGF-Yin et al.1 9 using the human breast cancer cell line MDA-MB-231 13-receptor-mediated signal transduction. These findings are in in which they exhibited that dominant-negative blockade of the concordance with those of others that have identified functional type II TGF-[3 receptor had no effect on the growth of local tumor receptors in TGF-j3 growth resistant cancers such as glioma 33 , yet significantly diminished metastasis to the bone.1 9 In our study, melanoma 34 and cervical carcinoma. 3 5 The intactness of Smad-histological analysis did not reveal any discernible differences in mediated gene transcription in the 4T1 mammary tumor cell line is the morphology or local invasiveness of the primary tumors besimilar to that reported in human melanoma cells in which Smad-tween mock-transfected (4T 1 -Zeo) and DNRII-expressing tumors. mediated gene transcription was shown to be independent of cell In addition, no histologic evidence of hematogenous metastases proliferation. 34 was observed in blood vessels adjacent to the primary tumors. The TGF-[3-induced morphological changes that we observed in These findings are not unexpected since hematogenous invasion of 4T1 mammary tumor cells are consistent with those reported by neoplastic cells is a relatively infrequent occurrence that is rarely others in transformed murine mammary epithelial cells,'5 murine documented histologically. A more reliable indicator of hematogcolon cancer cells' 4 and skin carcinoma cells1 6 Transforming growth factor-p3 (TGF[3) is a pleiotropic growth factor, which plays a critical role in modulating cell growth, differentiation and plasticity. There is increasing evidence that after cells lose their sensitivity to TGFf3-mediated growth inhibition, autocrine TGFI3 signaling may potentially promote tumor progression. Studies have shown that introduction of a dominant negative TGFI3 type II receptor (Tf3RII) in a variety of tumor cells can delay tumor formation and prevent the conversion of cells from an epithelial to a more invasive and metastatic mesenchymal phenotype. The purpose of this study is to identify the biochemical pathways perturbed by a dominant negative Tf3RII that are causally associated with the metastatic phenotype of tumors. In order to do that, the MDA-MB-231 human breast cancer cell line was stably transfected with either a kinase-dead Tf3RII-K277R (dnTI3RII) construct or the vector control. Affinity labeling of cell surface receptors wvith ' 2 5I-TGFI31 revealed an increase in the labeling of TI3RII on the surface of cells transfected with dnTr3RII compared to the vector control or parental cells, suggesting that the dnTI3RII was indeed expressed. This was confirmed by immunoprecipitating the affinity-labeled exogenous receptor via its HA tag. The function of the transgene was evaluated by i) examining phosphorylation and nuclear translocation of Smad2, a TGFI3 signal transducer, and ii) measuring transcription utilizing the TGFf3 responsive promoters, p3TP-lux and p(CAGA) 1 2 -1ux. These assays revealed that TGFf3-mediated Smnad2 phosphorylation, Smad2 nuclear translocation, and transcriptional responses were reduced in cells stably transfected with dnTI3RII compared to vector control. In addition, wound closure assays indicated that the basal migratory potential of dnTI3RII expressing cells was impaired. Biochemical experiments are currently underway to identify the signal transducers perturbed by the dnTf3RII expression which impair motility, and which may, in turn, be relevant to TGFj3-mediated invasion and metastases.
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Expression of a Kinase Inactive TGFP Type II Receptor Impairs Motility in Breast Cancer Cells Nancy Dumont, Andrei Bakin and Carlos L. Arteaga, Departments of Cancer Biology and Medicine, Vanderbilt University School of Medicine and Vanderbilt-Ingram Cancer Center.
Transforming growth factor-P3 (TGFP) is a pleiotropic growth factor, which plays a critical role in modulating cell growth, differentiation and plasticity. There is increasing evidence that after cells lose their sensitivity to TGFP-mediated growth inhibition, autocrine TGFP signaling may potentially promote tumor progression. Studies have shown that introduction of a dominant negative TGFP3 type II receptor (TPRII) in a variety of tumor cells can delay tumor formation and prevent the conversion of cells from an epithelial to a more invasive and metastatic mesenchymal phenotype. The purpose of this study is to identify the biochemical pathways perturbed by a dominant negative TP3RII that are causally associated with the metastatic phenotype of tumors. To accomplish this aim, the MDA-MB-231 metastatic human breast cancer cell line was stably transfected with either a kinase-dead TPRII-K277R (dnTf3RII) construct or the vector control. Affinity labeling of cell surface receptors with 125 I-TGF3 1 revealed an increase in the labeling of TPRII on the surface of cells transfected with dnTI3RII compared to the vector control or parental cells, suggesting that the dnTPRII was expressed. This was confirmed by immunoprecipitating the affinity-labeled exogenous receptor via its HA tag. The function of the transgene was evaluated by i) examining phosphorylation and nuclear translocation of Smad2, a TGFP3 signal transducer, and ii) measuring transcription utilizing the TGFP responsive promoters, p3TP-lux and p(CAGA) 12 -lux. These assays revealed that TGFP3-mediated Smad2 phosphorylation, Smad2 nuclear translocation, and transcriptional responses were reduced in cells stably transfected with dnTP3RII compared to vector control. In addition, wound closure assays indicated that the basal migratory potential of dnTj3RII expressing cells was impaired, independent of changes in proliferation. This impairment in motility appears to be TGFP specific in that it can be restored by expression of a constitutively active type I TGFI3 receptor, but not by constitutively active activin or BMP type I receptors. Biochemical experiments are currently underway to identify the signal transducers perturbed by dnTP3RII expression which impair motility, and which may, in turn, be relevant to TGFf3mediated invasion and metastases.
